List view / Grid view
According to a new report, the UK is leading the rest of Europe for early-stage clinical research into new medicines and vaccines, with more than 600 commercial clinical trials taking place in the NHS.
The UK’s newest life sciences asset, Health Innovation Research Alliance Northern Ireland (HIRANI), has been launched at a BIO reception.
Haseeb Ahmad from Novartis Pharmaceuticals has been confirmed as the new president of the The Association of the British Pharmaceutical Industry (ABPI).
The Association of the British Pharmaceutical Industry has called for a temporary ban on drugs exports in the event of a no-deal Brexit to prevent the NHS being hit by shortages...
The pharma industry has called for the government to act to ensure that patients receive their medications in the case of a ‘no deal’ situation...
Patients could find that supplies of their medicines will be disrupted when the UK leaves the EU, according to a new briefing published by the Brexit Health Alliance...
Disclosure rate of industry-sponsored clinical trials at 12 months has significantly improved year on year from 71% in 2009 to 93% in 2014, according to ABPI-sponsored study.
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
The Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), Mike Thompson responds to the UK’s Budget announcement...
The Association of the British Pharmaceutical Industry (ABPI) has admitted the American biotech bluebird bio, Inc. as a full member...
An exclusive column from the ABPI's Magda Papadaki about the implications of synthetic biology for the pharmaceutical industry...
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
The ABPI has responded to a joint letter from Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, published by the Financial Times, that outlined the UK Government’s plans for the regulation of medicines as the UK leaves the European Union (EU).
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
2 June 2017 | By Niamh Marriott, Junior Editor
Sara Rajeswaran has joined the Association of the British Pharmaceutical Industry as the new Executive Director of Government Affairs and Devolved Nations.
